TrialClinical and experimental immunology2015

A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia-reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery.

P Opfermann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.